Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor–Positive Human Epidermal Growth Factor 2–Negative Breast Cancer

Pembrolizumab for Early Triple-Negative Breast Cancer

Peter Schmid, Javier Cortés, Lajos Pusztai et al. · New England Journal of Medicine · 2020 · 3.1K citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline

Larissa A. Korde, Mark R. Somerfield, Lisa A. Carey et al. · Journal of Clinical Oncology · 2021 · 998 citations · Full text

Medicine, Endocrinology, Oncology +17

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer

New England Journal of Medicine · 2021 · 832 citations · Full text

Medicine, Oncology, Breast Oncology +15

A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer

David L. Rimm, Gang Han, Janis M. Taube et al. · JAMA Oncology · 2017 · 762 citations

Medicine, Oncology, Pathology +17

Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer

Rita Nanda, Minetta C. Liu, Christina Yau et al. · JAMA Oncology · 2020 · 706 citations · Full text

Medicine, Oncology, Pharmacology +16